Abstract: The present application provides for use of a somatosensory evoked potential (SEP) during the hyperacute stroke phase as marker for predicting the outcome of endovascular treatment in a patient suffering from acute ischemic stroke, wherein when the SEP ipsilateral to the stroke site has an amplitude from 60% to 100% with respect to the corresponding SEP contralateral to the stroke site this is indicative of good outcome of the endovascular treatment, whereas when the SEP ipsilateral to the stroke site has an amplitude from 0% to 20% with respect to the corresponding SEP contralateral to the stroke site this is indicative of bad outcome of the endovascular treatment.

Abstract: The present application provides for use of a somatosensory evoked potential (SEP) during the hyperacute stroke phase as marker for predicting the outcome of endovascular treatment in a patient suffering from acute ischemic stroke, wherein when the SEP ipsilateral to the stroke site has an amplitude from 60% to 100% with respect to the corresponding SEP contralateral to the stroke site this is indicative of good outcome of the endovascular treatment, whereas when the SEP ipsilateral to the stroke site has an amplitude from 0% to 20% with respect to the corresponding SEP contralateral to the stroke site this is indicative of bad outcome of the endovascular treatment.

Abstract: The invention relates to a CD5L-binding agent or a pharmaceutical composition thereof for use in the treatment of cancer by inhibiting macrophage M2 activation or promoting lymphocyte activation.

Abstract: It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

Abstract: The present invention provides a method for predicting subject's responsiveness to a corticosteroid medical regimen, prior to the start of the medical regimen, the method comprising the step of determining the amount of miR218-5p in an isolated test sample of the subject, wherein if no miR218-5p amount is present in the sample, it is indicative that the subject will be responder to the medical regimen, and if miR218-5p is detected in the test sample it is indicative that the subject will not respond to the medical regimen. The invention also provides the use of means for determining the amount of miR218-5p for predicting subject's responsiveness to a corticosteroid medical regimen.

Abstract: Topical composition for the treatment of mucosal lesions It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

Abstract: It relates to compositions comprising specific amounts of a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, and two thermoreversible adhesive agents, one of them being a poloxamer, wherein the weight ratio between the poloxamer and the hyaluronic acid or its salt is from 60:1 to 10:1; that may be used as a drug delivery system for the local delivery of active agents to the gastrointestinal tract. It also relates to delivery devices comprising them; and to their uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of tumor recurrence and reduction of inflammation in the gastrointestinal tract.

Abstract: Various examples of devices and kits for assisting in and illuminating medical procedures are disclosed. The devices may be attached to handheld medical tools. Also disclosed are various examples of medical procedures that may be carried out using the devices or kits. Also discloses are various examples for mounting auxiliary medical tools to a device mounted on a primary medical tool.

Abstract: The present invention provides an in vitro method for determining the prognosis in a patient suffering a heart failure disease, the method comprising the step of determining the level of soluble neprilysin (NEP) in a test sample of the patient.

Abstract: The present invention provides methods for selecting an individual with psoriasis (Ps) or psoriatic arthritis (PsA) who should receive or who is likely to respond to a treatment with an anti-tumor necrosis factor alpha (anti-TNF?) therapy. In addition, provided herein are methods for selecting an individual with Ps or PsA who should receive or who is likely to respond to a therapy that is not an anti-TNF? therapy, e.g., a non-anti-TNF? therapy for the treatment of Ps or PsA. Specifically, the methods of the present invention relate to detecting the presence of distinct alleles of the PDE3A-SLCO1C1 locus which are associated with a clinical response to an anti-TNF? therapy or a non-anti-TNF therapy in patients with Ps or PsA.

Abstract: The present invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain stroke. Particularly the invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain strokes wherein the drug prepared with apotransferrin is for administration by vascular route, preferably intravenous or intraarterial.

Abstract: Devices and methods for stimulating mechanically or electromechanically stem cell monolayer and 3D cultures for tissue engineering applications are disclosed. A bracket is proposed to be used in a disposable stimulation device. A disposable stimulation device is also proposed for accommodating a cell culture in a flexible area. Finally, an apparatus is proposed to mechanically extend the disposable stimulation device to induce mechanical stimulation. Additionally, a pair of electrodes placed at two opposing sides of the flexible area creates an electric field to induce electrical stimulation. Accordingly, a method to stimulate electromechanically a cell culture is proposed.

Abstract: The present invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain stroke. Particularly the invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain strokes wherein the drug prepared with apotransferrin is for administration by vascular route, preferably intravenous or intraarterial.

Abstract: Specific alterations in BChE gene have been found which allow determining whether a patient suffers from dementia with Lewy bodies (DLB), and allow distinguishing it from Alzheimer's disease. The invention provides an in vitro method for the diagnosis of DLB comprising determining in a biological sample from a subject, the genotype of the following alterations in butyrylcholinesterase (BChE) gene: the polymorphic sites at position 68974 in NCBI Accession Number NG_009031 (i.e. position 934 in SEQ ID NO: 28), and the polymorphic sites 3687, 4206, 4443, and the poly-thymine region at positions 4780 to 4786, said positions with reference to NCBI Accession Number NG_009031 (i.e. positions 3687, 4206 and 4443 respectively in SEQ ID NO: 1), which corresponds to the nucleotide sequence of human BChE gene.

Abstract: The present invention provides a biosafe and useful vector to transfer genetic material to CD14+ mononuclear cells (monocytes and monocyte-derived macrophages) in an efficient and specific manner. The embodiment of the invention makes use of the chimeric human adenovirus vectors 5 carrying the short fiber of enterotropic Ad40 to transfer genetic material to the target CD14+ mononuclear cells.